Current trials

Analysing The Results

Cancer Trials

Brain Cancer

  • BPA: A Cancer Research UK pharmacokenetic study of p-boronophenylalanine (BPA) in patients with high glioma of optimise uptake paramaters for clinical trials of boron neutron capture therapy
  • BEACON: A randomized phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
  • BSG: A phase II multi-centre study of concomitant and prolonged adjuvant temozolomide with radiotherapy in diffuse pontine gliomas
  • CPT: CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients with Choroid Plexus Tumors
  • Ependymoma II: An International Multi Centre Clinical Program for the diagnosis and treatment of children, adolescents and young adults with  Ependymoma
  • GD2: A Phase I/II dose schedule finding study of ch14.18/CHO continuous infusion combined with subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma
  • HART: Hyperfractionated Accelerated Radiotherapy (hart) with chemotherapy (cisplatin, ccnu, vincristine)
    for metastatic (m1-3) medulloblastoma (CNS 2001 06)
  • Infant Brain: Management of children aged less than 3 years with a brain tumour (CNS 9204)
  • INTREPID: A phase I dose escalation study of intrathecal Etoposide as a continuous infusion investigating duration and rate of infusion in patients with leptomeningeal metastatic brain cancer
  • LGG2: Cooperative multicenter Study for Children and Adolescents with Low Grade Glioma SIOP-LGG 2004
  • LowGrade Glioma: Low Grade Glioma (CNS 1997 02)
  • LUDO: A phase IIa study of 177 Lutetium dotateate in children with primary refractory or relapsed high risk neuroblastoma
  • PNET 4: A prospective randomised controlled trial of hyperfractionated versus conventionally fractionated radiotherapy in standard risk medulloblastoma

Breast Cancer

  • ABC: Adjuvant Breast Cancer trial: UKCCCR randomised trial of adjuvant endrocrine therapy and chemotherapy in women with early breast cancer.
  • aTTom: Adjuvant Tamoxifen Treatment Offer More: - to assess the reliably balance of benefits and risk of prolonging adjuvant tamoxifen treatment by 5 years for women with breast cancer.
  • AZURE: Does Adjuvant Zoledronic acid redUce REcurrence in patients with high-risk, localised breast cancer?
  • BR3002: Adjuvant radiotherapy and tamoxifen in conservative management of early breast cancer.
  • Cambridge Breast Cancer Trial: Investigations of radiotherapy dose inhomogeneity and cosmetic outcome in pateints with early breast cancer: a randomised controlled trial.
  • LORIS: A Phase III trial of surgery versus active monitoring for low risk Ductal Carcinoma in Situ (DCIS).
  • NEAT: National breast cancer study of epirubicin plus CMF versus classical CMF aduvant therapy.
  • NEAT-A: A multicentre Phase II feasibility study of accelerated chemotherapy - sequential epirubicin followed by IV CMF - using pegfilgrastim for women with early stage breast cancer.
  • NEO-EXCEL: Neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER positive postmenopausal early breast cancer.
  • Neo-tAnGo: A neoadjuvant study of sequential epirubicin + cyclophosphamide and paclitaxel ± gemcitabine in the treatment of high risk early breast cancer with molecular profiling and candidate gene analysis
  • PG-SNPs: The pharmacogenetics of early breast cancer chemotherapy
  • PHAB-PILOT: Physical activity and breast cancer - pilot research protocol
  • PHATE: The level of physical activity in women attending breast cancer follow up clinic
  • ROSCO: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer
  • SECRAB: Sequencing of Chemotherapy and Radiotherapy in Adjuvant Breast cancer
  • TACT2: Trial of Accelerated adjuvant ChemoTherapy with capecitabine in early breast cancer
  • tAnGo: A randomised phase III trial of gemcitabine in paclitaxel-containing epirubicin based adjuvant chemotherapy for women with early stage breast cancer
  • TEAM: An open label randomised multicentre comparative trial of 5 years adjuvant exemestane treatment versus adjuvant tamoxifen followed by exemestane in postmenopausal women with early stage breast cance

Embryonic Tumour

  • HRNBL: High risk neuroblastoma study 1 of SIOP- Europe (SIOpen) (NB 2002 06)
  • Retinoblastoma: A data collection study to compare the outcome for children with advanced nnilateral retinoblastoma treated with or without post-enucleation chemotherapy +/- radiotherapy on RB 2005 11 with historical controls receiving no additional therapy
  • TVD: Topotecan-Vincristine-Doxorubicin in children with stage 4 neuroblastoma failing to respond to COJEC
    (NB 2006 05)
  • Unresectable NB: Treatment of children over the age of 1 year with unresectable localised neuroblastoma without MYCN amplification

Gastrointestinal Cancer

  • NBI: Randomised, controlled trial of Narrow Band Imaging with magnification (NBI) versus white light endoscopy for dysplasia detection in ulcerative colitis patients with an established diagnosis of primary sclerosing cholangitis (PSC)
  • QUASAR 1: AA UKCCCR study of adjuvant chemotherapy for colorectal cancer.  All eligible patients with resected colorectal cancer, no distant metastases and a definite-indication for chemotherapy will be randomised to high or low dose folinic acid, with or without additional levamisole

Germ Cell Cancer

  • GC Survivors: Cross-sectional evaluation of outcome following extra-cranial germ cell tumours treated according to UKCCGGC 7901 (GC I) and GC 8901 (GC II) Protocols
  • GC2: GC- 2 (GC 1989 01): Germ Cell Tumour Study II
  • GC3: GC-3 - Protocol for the Treatment of Extracranial Germ cell Tumours in Children & Young Adolescents  (GC 2005/04)
  • SIOP CNS GCT II: Prospective trial for the diagnosis and treatment of children, adolescents and young adults with intracranial germ cell tumours

Gyneaecological Cancer

  • DESKTOP III: A randomized multicenter study to compare the efficacy of additional tumour debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer
  • EPIVIN: Phase II clinical trial investigating the use of epigallocatechin-3-gallate (Veregen) in the treatment of vulval intraepithelial neoplasia
  • Neo-Escape: A randomised feasibility study of extended chemotherapy with neoadjuvant carboplatin followed by adjuvant paclitaxel and gemcitabine vs gemcitabine and carboplatin followed by paclitaxel alone, in patients with advanced ovarian cancer

Haematology Malignancies

  • ALCL 99: International protocol for the treatment of Childhood Anaplastic Large Cell Lymphoma (ALCL 99)
  • ALCL Relapse: Treatment protocol for relapsed anaplastic large cell lymphoma of childhood of childhood and adolescence (NHL 2006 01)
  • AZTEC: A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed therapy with corticosteroids
  • BaP: Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers
  • BREVITY: A phase II study of brentuximab vedotin (SGN-35) using a responce adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity
  • CALiBRe: Assessment of the mechanism of action of CAL-101 in B-cell receptor pathway inhibition in CLL
  • CLARITY: Assessment of Venetoclax (ABT-199) in combination with Ibrutinib in relapsed/refractory Chronic Lymphocytic Leukaemia
  • CLL pathogenesis: Study of the pathogenesis of Chronic Lymphocytic Leukaemia
  • CLOUD: Phase I dose escalation study of Clofarabine and Liposomal Daunorubicin in childhood and adolescent AML
  • CTAg: Study of the immune response to haematological malignancies
  • CyCLLe: An phase II trial of Cyclosporin A in early adverse risk CLL
  • De-Iron: A phase 2 study of the efficacy and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent Myelodysplastic Syndromes
  • ELASTIC: A phase Ib study of Eltrombopag and Azacitidine in patients with high risk myelodysplastic syndromes and related disorders
  • Euro LB 02: Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL)
  • EuroNet PHL-C1: First International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents
  • EuroNet PHL-LP1: First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin’s Lymphoma in Children and Adolescents
  • FIGARO: A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation
  • HA-1: A phase I clinical trial of the vaccination of healthy human volunteers against the minor histocompatibility antigen (mHAg) HA-1 using a DNA and MVA ‘prime/boost’ regimen
  • HD-3: United Kingdom Children’s Cancer Study Group (UKCCSG) protocol for the treatment of children and adolescents with Hodgkin’s disease
  • HLH 2004: Treatment protocol of the second international HLH study 2004 (LCH 2006 02)
  • IciCLLe: Assessment of the mechanism of action of PCI-32765 in B-cell receptor pathway inhibition in CLL
  • Immune reconst: A Study of Immune Reconstitution Following Stem Cell Transplant
  • Inter B NHL2010: Intergroup trial for children or adolescents with B-Cell NHL or B-AL: evaluation of rituximab in high risk patients
  • Interfant 06: International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukaemia
  • Interfant 99: Intrenational collaborative treatment protocol for infants under one year with acute lymphoblastic leukaemia (LK 1999 05)
  • LCH 3: Treatment protocol of the third international study for Langerhans Cell Histiocytosis
  • LenaRIC: Phase II study of the adjunctive use of lenalidomide in patients undergoing reduced intensity conditioning allogeneic transplantation for multiple myeloma
  • MAJIC: A randomised study of best available therapy versus JAK inhibition in patients with high risk polycythaemia vera or essential thrombocythaemia who are resistant or intolerant to hydroxycarbamide
  • Matchpoint: MAnagement of Transformed CHronic myeloid leukaemia: POnatinib and INTensive chemotherapy: a feasibility study
  • MiniAlloGlivec: A phase I/II study of the use of glivec in patients undergoing reduced intensity allografting for chronic myeloid leukaemia
  • Myechild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia -Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy
  • NECTAR: A Phase I trial of NECTAR (Nelarabine, Etoposide and cyclophosphamide in T-ALL relapse): A joint study of TACL and POETIC.
  • PICLLe: Phase I/II clinical trial to assess the efficacy and safety of olaparib, a PARP-inhibitor, in relapsed and refractory chronic lymphocytic leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patients with T-prolymphocytic leukaemia and mantle cell lymphoma
  • PHAZAR: A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN.
  • RAvVA: Phase II randomised trial of 5-azacitidine versus vorinostat in vombination with 5-azacitidine in patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes for intensive chemotherapy
  • RICAZA: Phase II study of the tolerability of adjunctive Azacitidine in patients undergoing reduced intensity allogeneic stem cell transplantation for Acute Myeloid Leukaemia
  • ROMAZA: Phase I trial of Romidepsin plus Azacitidine combination therapy in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible forconventional chemotherapy
  • RomiCar: Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma
  • TIER: A Phase I/II Study of Thiotepa, Ifosphamide, Etoposide and Rituximab for the treatment of relapsed and refractory primary central nervous system lymphoma
  • TORCH: A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed/refractory Diffuse Large B cell Lymphoma (DLBCL).
  • TRICE: Phase I/II study of the adjunctive use of Nilotinib in patients undergoing reduced intensity allogeneic transplantation for Imatinib resistant or intolerant Chronic Myeloid Leukaemia
  • TYKI: An investigation into the immunomodulatory effects of tyrosine kinase inhibitors (imatinib, dasatinib and nilotinib) on patients with chronic myeloid leukaemia
  • val/aza: Phase II study of the tolerability and efficacy of the histone deacetylase inhibitor sodium valproate administered in conjunction with 5-azacitidine, Theophylline and ATRA (all trans retinoic acid) in patients with Acute Myeloid Leukaemia and High Risk Myelodysplasia
  • Valproate: Phase II study of the tolerability and efficacy of the histone deacetylase inhibitor Sodium Valproate in conjunction with ATRA (all trans retinoic acid) in patients with Acute Myeloid Leukaemia
  • VIOLA: A phase 1 trial of combined azacitidine and lenalidomide salvage therapy in patients with AML who relapse after allogeneic stem cell transplantation

Head and Neck

  • ArChIMEDEs: Accelerated Hypofractionation, Chemotherapy, Intensity Modulation and Evaluation of Dose Escalation in Oropharyngeal Cancer
  • CompARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
  • Oromouth: HPV prevalence in the mouth and oropharynx of the tonsillectomy population
  • PACIFIC: Phase Ib trial of Atu027 in Combination with Cisplatin, 5-FU and Cetuximab in Patients with Head and Neck Cance

Hepatocellular Carcinoma

  • ACTICCA01: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma
  • BILCAP: A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer
  • ESPAC-1: A randomised trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
  • ESPAC-3: Adjuvant chemotherapies in respectable pancreatic cancer
  • ESPAC-QoL: Development of outcome measure (ESPAC-QoL) specific to quality of life of patients with pancreatic cancer
  • GEMCAP: A phase III multicentre randomised trial comparing  gemcitabine alone or in combination with capecitabine for the treatment of patients with advanced pancreatic cancer
  • HBIg: Hepatitis B immunoglobulin (HBIg) withdrawal from combination Lamivudine (LAM) / HBIg prophylaxis in liver transplant recipients
  • Hep-1: A randomised clinical trial evaluating the benefits of doxorubicin chemoembolisation versus systemic doxorubicin in patients with unresectable advanced hepatocellular carcinoma
  • Homing of DCs: A Phase 1` study of the homing of mature autologous dendritic cells in vivo in patients with hepatocellular carcinoma or liver metastases
  • IMMUNOTACE: A phase II randomised clinical trial of conditioning cyclophosphamide and chemoembolisation with or without vaccination with Dendritic Cells pulsed with HepG2 lysate in vivo in patients with Hepatocellular Carcinoma
  • SIOPEL 3: Hepatoblastoma and hepatocellular carcinoma SIOPEL 3 (LT 1998 01)
  • SIOPEL 4: Intensified pre-operative chemotherapy and radical surgery for high risk hepatoblastoma
  • SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for standard risk hepatoblastoma
  • TACE-2: A randomised placebo-controlled, double-blinded, phase III trial of sorafenib in combination with transarterial chemoembolisation in hepatocellular cancer

Histiocytosis

  • LCHIV: International collaborative treatment protocol for children and adolescents with langerhans cell histiocytosis (LCH-IV)

Lung Cancer

  • BTOG2: A British Thoracic Oncology Group, multi-centre, phase III trial of Gemcitabine plus Cisplatin at 80mg/m versus Gemcitabine plus Cisplatin at 50mg/m versus Gemcitabine plus Carboplatin AUC 6 in stage IIIB/IV non-small cell lung cancer.
  • Matrix: National Lung Matrix Trial: Multi-drug, genetic marker directed, non-comparative multicentre, multi-arm Phase II trial in Non-Small Cell Lung Cancer
  • NOURISH P2: Improving the management of cachexia in patients with advanced lung cancer: Does the introduction of  beta-hydroxy-beta-methylbutyrate supplementation improve nutritional status and quality of life?
  • SPECIAL: Does early referral of patients with metastatic non-small cell lung cancer to UK specialist palliative care
    services make a difference in their quality of life or survival?
  • STOMP: Small cell lung cancer trial of Olaparib (AZD2281) as maintenance programme: a randomised, double blind, multicentre phase II trial

Mixed Primary Cancer

  • FOAM: FOlic Acid supplementation in the management of Menopausal symptoms in cancer survivors and healthy postmenopausal women
  • Immunocore: Generation of high affinity T cell receptors directed against human tumour associated antigens
  • MVA (EBV): A phase I, dose escalation trial of recombinant modified Vaccinia Ankara (MVA)-based vaccine encoding Epstein-Barr virus target antigen
  • MVA 1b: A Cancer Research UK Phase Ib trial to determine the safety, tolerability and immunogenicity of extended schedule vaccination with MVA-EBNA1/LMP2 in patients with Epstein Barr Virus positive nasopharyngeal carcinoma
  • NOURISH Pilot 1: A pilot study to determine changes in lean body mass
  • ORANGE: ORal Antibiotics for Neutropenic sepsis Giving Early hospital discharge
  • SIGNIFICANT II: Feasibility Study - Colonization by antibiotic-resistant bacteria in patients undergoing cytotoxic chemotherapy for solid cancers: pilot study for a randomized controlled trial of antibiotic prophylaxis
  • SIGNIFICANT: A randomised, prospective double-blind, placebo-controlled trial of prophylactic oral levofloxacin following chemotherapy for lymphoma and solid tumours
  • WARP: A multicentre prospective randomised trial of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters

Sarcoma

  • Axi-STS: A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas
  • EE2012: Euro Ewing 2012 - International randomised controlled trial for the treatment of newly diagnosed Ewing's sarcoma family of tumours
  • EE99: EUROpean Ewing tumour working initiative of national groups - Ewing tumour studies 1999Patie
  • MMT 98 PK: MMT 98 PK (PK 2000 05)
  • rEECur: An International Randomised Controlled Trial of Chemotherapy for the treatment of reccurent and primary refractory Ewing sarcoma
  • RMS 2005: A protocol for non metastatic rhabdomyosarcoma
  • SCART: Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination with Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi’s sarcoma (KS)
  • SIOP MMT 95: SIOP MMT 95 (STS 1995 07): For Rhabdomyosarcoma and other malignant soft tissue tumours of childhood
  • VIT0910: International Randomised Phase II Trial of the Combination of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in Patients with Refractory or Relapsed Rhabdomyosarcoma
  • Vortex: Randomised trial of dose and volume of post-operative radiotherapy given to adult patients with extremity soft tissue sarcoma

Skin Cancer

  • DC-1: A phase I study of immunotherapy for patients with metastatic melanoma using dendritic cells transfected with a plasmid encoding two melanoma antigens
  • DC-2: A study of immunotherapy for patients with metastatic melanoma using dendritic cells activated with plasmids encoding multiple antigens
  • LIMIT1: Effect of topical imiquimod on lentigo maligna
  • SPOT: Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments (SPOT): a feasibility study
  • UKMCC-01: A phase II study of pazopanib in metastatic merkel cell carcinoma

Urological Cancer

  • ADIUVO: Efficacy of adjuvant mitotane treatment in prolonging recurrence-free survival in patients with adrenocortical carcinoma at low-intermediate risk of recurrence
  • AdUP: A phase 1 clinical trial of a replication defective adenovirus (type 5) vector expressing nitroreductase and GMCSF (AdNRGM) given via brachytherapy, followed by CB1954, in patients with locally relapsed hormone-refractory prostate cancer
  • ADVICE: A feasibility study of molecular markers in patients with muscle invasive transitional cell carcinoma of the bladder entered into neo-adjuvant chemotherapy trial
  • AMRCC: A study of angiogenesis markers in patients with Renal Cell Carcinoma therapy with sunitinib: correlations with tumour response and prognosis
  • BC2001: A randomised phase III study of radiotherapy with or without synchronous chemotherapy in muscle invasive bladder cancer
  • BCPP/SELENIB: Bladder cancer prognosis programme and phase III trial of vitamin E and selenium
  • CANTATA: A multicentre phase II randomised controlled trial evaluating docetaxel re-challenge versus cabazitaxel for the treatment of metastatic castrate refractory prostate cancer, previously treated with docetaxel at inception of primary hormone therapy
  • HYMN: A randomised controlled Phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guérin or standard therapy in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance bacillus Calmette-Guérin therapy
  • PAZ02: A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and Performance Status 2 (ECOG)
  • Relapsed Wilms: Protocol for the treatment of relapsed and refractory Wilms tumour and clear cell sarcoma of the Kidney (CCSK) UKW-R  (WT 2001 02)
  • SIOP WILMS: SIOP nephroblastoma (wilms tumour) clinical trial and study
  • Trapeze: A randomised phase II/III  study of docetaxel plus prednisolone vs docetaxel plus prednisolone plus zoledronic acid vs docetaxel plus prednisolone plus strontium-89 vs docetaxel plus prednisolone plus zoledronic acid plus strontium-89 in hormone refractory prostate  cancer metastatic to bone
  • TUBA: A study of biomarkers in muscle invasive bladder cancer
  • TUXEDO: Phase I/II feasibility study of cetuximab with  5-FU and mitomycin c or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer
  • WT3: WT-3 (WT 1991 01): Trial of preoperative chemotherapy in biopsy proven Wilms' tumour versus immediate nephrectomy

Non-Cancer Trials

Non-Cancer

  • ITX5061: Phase II study of Hepatitis C Virus (HCV) entry inhibitor (ITX5061) in liver transplant recipients with HCV infection
  • LEAN: A 48-week phase II, randomised, double blinded placebo controlled, parallel-group, multi centre trial  on liraglutide's safety, efficacy and action on liver histology and mechanism in overweight patients with non-alcohlic steatohepatitis, with or without type II diabetes
  • MINT: Managing injuries of the neck trial
  • PARA: An intervention fostering autonomous motivation, physical activity and cardiovascular fitness in rheumatoid arthritis
  • PEPtalk 2: Pilot of a randomised controlled trial to compare VZIG and aciclovir as post-exposure prophylaxis against chickenpox in children with cancer
  • REALISTIC: A multicentre, phase II, open label, randomised controlled trial of repeated autologous infusions of g-CSF mobilised CD133+ bone marrow stem cells in patients with cirrhosis
  • VAP-1: Targeting vascular adhesion protein-1 (VAP-1) for the treatment of liver fibrosis: a study of efficacy and mechanisms in patients with primary sclerosing cholangitis (PSC)